Company intelligence / Profile preview
TriSalus Life Sciences
Denver, Colorado, United Statestrisaluslifesci.com ↗
- Ownership
- Public · TLSI
- Employees
- ~199
- Development stage
- Commercial
01
Overview
TriSalus has two FDA-cleared devices using proprietary Pressure-Enabled Drug Delivery technology. The company is also developing nelitolimod (SD-101), an investigational TLR9 agonist immunotherapy, with Phase 1 clinical trials completed and Phase 2 trials in progress for various cancer indications.
- Therapeutic areas
- Oncology
- Modalities
- ImmunotherapyDrug Delivery Technology
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
MD Anderson Cancer Center
04
Financials
- Market cap
- $217.4M
- Total revenue
- $45.2M
- Enterprise value
- $205.5M
Beyond the preview
Go deeper on TriSalus Life Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TriSalus Life Sciences.